<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">31196</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Diagnostic value of serum markers of fibrosis in chronic liver diseases</article-title><trans-title-group xml:lang="ru"><trans-title>Диагностическая значимость сывороточных маркеров фиброза при хронических заболеваниях печени</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vinnitskaia</surname><given-names>E V</given-names></name><name xml:lang="ru"><surname>Винницкая</surname><given-names>Е В</given-names></name></name-alternatives><email>evinn@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Drozdov</surname><given-names>V N</given-names></name><name xml:lang="ru"><surname>Дроздов</surname><given-names>В Н</given-names></name></name-alternatives><email>vndrozdov@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Iunusova</surname><given-names>Iu M</given-names></name><name xml:lang="ru"><surname>Юнусова</surname><given-names>Ю М</given-names></name></name-alternatives><email>youldooz777@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Varvanina</surname><given-names>G G</given-names></name><name xml:lang="ru"><surname>Варванина</surname><given-names>Г Г</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shaposhnikova</surname><given-names>N A</given-names></name><name xml:lang="ru"><surname>Шапошникова</surname><given-names>Н А</given-names></name></name-alternatives><email>natalka1212@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Petrakov</surname><given-names>A V</given-names></name><name xml:lang="ru"><surname>Петраков</surname><given-names>А В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tkachenko</surname><given-names>E V</given-names></name><name xml:lang="ru"><surname>Ткаченко</surname><given-names>Е В</given-names></name></name-alternatives><email>ElenV.Tkachenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lazebnik</surname><given-names>L B</given-names></name><name xml:lang="ru"><surname>Лазебник</surname><given-names>Л Б</given-names></name></name-alternatives><email>ElenV.Tkachenko@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ЦНИИ гастроэнтерологии Департамента здравоохранения Москвы</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2013</year></pub-date><volume>85</volume><issue>2</issue><issue-title xml:lang="en">VOL 85, NO2 ()</issue-title><issue-title xml:lang="ru">ТОМ 85, №2 (2013)</issue-title><fpage>27</fpage><lpage>31</lpage><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/31196">https://ter-arkhiv.ru/0040-3660/article/view/31196</self-uri><abstract xml:lang="en"><p>AIM: To estimate the diagnostic value (DV) of direct markers of liver fibrosis, such as type IV collagen (C-IV), hyaluronic acid (HA), tissue inhibitor of metalloproteinases-1 (TIMP-1) in combination with indirect markers of fibrosis, such as alanine aminotransferase (АLT), aspartate aminotransferase (AST), and γ-glutamyl transpeptidase (γ-GTP), alkaline phosphatase (ALP), platelets, tumor necrosis factor-α (TNF-α) in evaluating liver fibrosis/MATERIAL AND METHODS: Sixty-seven patients with chronic diffuse liver diseases were examined. ALT, AST, γ-GTP, and ALP were determined as indirect indicators of fibrosis. The levels of TIMP-1, HA, C-IV, and TNF-α were estimated by ELISA; the stage of fibrosis was determined by the results of indirect liver ultrasound fibroelastography (FE)/RESULTS: According to the results of FE, the patients were divided into 2 groups: 1) (n=25) F≤2 METAVIR and 2) (n=42) F3-F4. While estimating DV of severe fibrosis stages (F3-F4), the area under the ROC curve (AUC) increased for platelets, HA, and C-IV. DV of ALT, AST declined with the higher degree of fibrosis. The highest ratio of test specificity and sensitivity (TSp and TSen) and AUC were observed for AST and HA. ALT and platelets showed low TSen, and TNF-α and TIMP-1 had no TSp. For evaluation of fibrosis (F4), a HA increase of over 57.7 ng/ml had 92.6% TSen and 67.5% TSp; for a C-IV elevation of above 133.1mkg/l, TSen was 85.2%, TSp was 57.5%; for a TIMP-1 rise from 24.4 ng/ml, TSen was 74.1% and TSp was 62.5%. For the diagnosis of fibrosis (F4) with a HA rise of more than 57.7 ng/ml, DV of a positive test was 65.8 (48.65-80.4; 95% CI) and that of a negative test was 93.1 (76.8-99.2; 95% CI). Thus, the negative rather than positive test results are of great diagnostic value for evaluation of the degree of fibrosis/CONCLUSION: The results of the investigation convincingly suggest that examination of the serum markers of fibrosis allows one to estimate with a high probability its presence and severity in patients with hepatic cirrhosis. The so-called direct markers (substances reflecting the biochemistry and regulation of fibrogenesis) are undoubtedly of great diagnostic value.</p></abstract><trans-abstract xml:lang="ru"><p>Резюме. Цель исследования. Определение диагностической значимости прямых маркеров фиброза печени: коллагена IV типа (КIV), гиалуроновой кислоты (ГК), тканевого ингибитора металлопротеиназы-1 (ТИМП-1) в сочетании с непрямыми показателями фиброза: аланинаминотрансфераза (АлАТ), аспартатаминотрансфераза (АсАТ), γ-глутамилтранспептидаза (ГГТП), щелочная фосфатаза (ЩФ), тромбоциты, α-фактор некроза опухоли (α-ФНО) в оценке фиброза печени. Материалы и методы. Обследовали 67 больных хроническими диффузными болезнями печени. В качестве непрямых показателей фиброза определяли АлАТ, АсАТ, ГГТП, ЩФ. Уровень ТИМП-1, ГК, КIV, α-ФНО определяли при помощи иммуноферментного анализа, стадию фиброза - по результатам непрямой ультразвуковой фиброэластографии печени. Результаты. По результатам ФЭ больные были распределены на 2 группы: 1-я (n=25) F≤2 по шкале Metavir и 2-я (n=42) - F3-F4. При оценке диагностической значимости (ДЗ) тяжелых стадий фиброза (F3-F4) площадь под характеристической кривой (AUC) увеличивалась для тромбоцитов, ГК и КIV. ДЗ активности АлАТ и АсАТ снижалась по мере нарастания тяжести фиброза. Наилучшее соотношение специфичности теста (СТ), чувствительности теста (ЧТ) и AUC отмечались для активности АсАТ и уровня ГК. Активность АлАТ и число тромбоцитов имели низкую ЧТ, а уровни α-ФНО и ТИМП-1 не обладали СТ. Для оценки фиброза (F4) повышение уровня ГК более 57,7 нг/мл имело ЧТ 92,6% и СТ 67,5%; для повышения уровня КIV более 133,1 мкг/л ЧТ составила 85,2%, СТ - 57,5%; для повышения активности ТИМП-1 более 24,4 нг/мл - ЧТ 74,1% и СТ 62,5%. Для диагностики фиброза (F4) повышение уровня ГК (более 57,7 нг/мл) ДЗ положительного результата теста составила 65,8 при 95% доверительном интервале (ДИ) от 48,65 до 80,4, а ДЗ отрицательного результата теста - 93,1 при 95% ДИ от 76,8 до 99,2. Таким образом, для оценки тяжести фиброза большее диагностическое значение имел не положительный, а отрицательный результат теста. Заключение. Результаты исследования убедительно свидетельствуют, что изучение сывороточных маркеров фиброза позволяет с высокой вероятностью оценить его наличие и тяжесть у больных циррозом печени. Большую диагностическую значимость, безусловно, представляют так называемые прямые маркеры - вещества, отражающие биохимию и регуляцию фиброгенеза.</p></trans-abstract><kwd-group xml:lang="en"><kwd>liver fibrosis</kwd><kwd>serum markers of fibrosi</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>фиброз печени</kwd><kwd>сывороточные маркеры фиброза</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Popper H. Present day morphology of cirrhosis. Gastroenterology 1958; 34 (4): 661-666.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Popper H. Kent G. Fibrosis in chronic liver disease. Clin Gastroenterol 1975; 4 (2): 315-332.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Soyer M.T., Ceballos R., Aldrete J.S. Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. Surgery 1976; 79 (5): 601-604.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Friedman S.L., Roll F.J., Boyles J. et al. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985; 82: 8681-8685.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Wake K. "Sternzellen" in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat 1971; 132: 429-462.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Friedman S.L. Liver fibrosis - from bench to bedside. J Hepatol. 2003; 38: 38-53.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pinzani M., Vizzutti F. Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis 2008; 12 (4): 901-913.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Snowdon V.K., Fallowfield J.A. Models and mechanisms of fibrosis resolution. Alcohol Clin Exp Res 2011; 35 (5): 794-799.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Brenner D. A., Seki E., Taura K. et al. Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res 2011; 41 (7): 683-686.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Roderfeld M., Koc A., Rath T. еt al. Induction of matrix metalloproteinases and TLR2 and 6 in murine colon after oral exposure to Mycobacterium avium subsp. Paratuberculosis. Microbes Infect 2012; 14 (6): 545-553.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Wang H., Lafdil F., Wang L. et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci 2011; 1 (1): 14.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Povero D., Busletta C., Novo E. et al. Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 2010; 25 (8): 1075-1091.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Friedrich-Rust M., Rosenberg W., Parkes J. et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010; 9 (10): 103.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Rosenberg W. M., Voelker M., Thiel R. et al. European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127 (6): 1704-1713.</mixed-citation></ref></ref-list></back></article>
